Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down on Insider Selling

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $13.50, but opened at $13.22. Stoke Therapeutics shares last traded at $13.52, with a volume of 131,390 shares trading hands.

Specifically, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the transaction, the insider now directly owns 6,981 shares in the company, valued at $33,508.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, General Counsel Jonathan Allan sold 5,126 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the sale, the general counsel now directly owns 2,598 shares in the company, valued at $34,293.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company’s stock, valued at $33,508.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,741 shares of company stock worth $223,115. Company insiders own 12.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Needham & Company LLC increased their target price on shares of Stoke Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Wedbush upped their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 26th. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Finally, Canaccord Genuity Group upped their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $19.63.

Get Our Latest Stock Analysis on Stoke Therapeutics

Stoke Therapeutics Price Performance

The company has a market cap of $605.60 million, a PE ratio of -5.52 and a beta of 0.77. The company’s 50 day simple moving average is $6.75 and its two-hundred day simple moving average is $5.25.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock worth $8,671,000 after purchasing an additional 17,814 shares in the last quarter. Barclays PLC lifted its position in shares of Stoke Therapeutics by 365.3% during the fourth quarter. Barclays PLC now owns 39,271 shares of the company’s stock worth $206,000 after purchasing an additional 30,831 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of Stoke Therapeutics by 33.7% during the fourth quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock worth $5,985,000 after purchasing an additional 286,686 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $90,000. Finally, Birchview Capital LP lifted its position in shares of Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after purchasing an additional 125,000 shares in the last quarter.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Articles

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.